Qilu Pharmaceutical Co., Ltd. Drug Pipeline

Qilu Pharmaceutical Co., Ltd. maintains a substantial clinical development portfolio, with 92 active trials out of 118 total trials registered since 2008. These active programs span from Phase 1 through Phase 4, with a distribution of 38, 26, 40, and 2 trials respectively. The portfolio covers 11 therapeutic areas, but is heavily concentrated in oncology, which accounts for 61% of active programs (56 trials). Within oncology, the leading indications are solid tumor (advanced) with 18 active trials, non-small cell lung cancer (NSCLC) with 6 active trials including 3 in Phase 3, multiple myeloma with 5 active trials including 2 in Phase 3, colorectal cancer with 4 active trials including 2 in Phase 3, and pancreatic cancer with 3 active trials including 1 in Phase 3. Beyond oncology, other therapeutic areas with notable activity include immunology (7 active trials), metabolic disorders (6 active trials), central nervous system disorders (4 active trials), cardiovascular disease (3 active trials), and respiratory disease (3 active trials). The significant number of Phase 3 trials in oncology suggests a potential for near-term clinical catalysts in this area.